19/10/2026
Closing the Peptide Gap: SAHPRA's New Guideline on Synthetic Peptides
SAHPRA has issued its first guideline on synthetic peptides, setting out how these medicines can be lawfully brought to market. The message is clear: the route is registration, not compounding. Partners, Dohmen, Pereira and Bagnall unpack what it means for originators, generics manufacturers and pharmacies.
Read the Regulatory Update: https://www.adams.africa/danie-dohmen/closing-the-peptide-gap-sahpras-new-guideline-on-synthetic-peptides/